These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

538 related items for PubMed ID: 21109069

  • 1. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines.
    Whaley KJ, Hanes J, Shattock R, Cone RA, Friend DR.
    Antiviral Res; 2010 Dec; 88 Suppl 1():S55-66. PubMed ID: 21109069
    [Abstract] [Full Text] [Related]

  • 2. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets.
    Garg S, Goldman D, Krumme M, Rohan LC, Smoot S, Friend DR.
    Antiviral Res; 2010 Dec; 88 Suppl 1():S19-29. PubMed ID: 21109064
    [Abstract] [Full Text] [Related]

  • 3. Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: Development of dual-protection technologies.
    Friend DR, Doncel GF.
    Antiviral Res; 2010 Dec; 88 Suppl 1():S47-54. PubMed ID: 21109068
    [Abstract] [Full Text] [Related]

  • 4. Advances in microbicide vaginal rings.
    Malcolm RK, Edwards KL, Kiser P, Romano J, Smith TJ.
    Antiviral Res; 2010 Dec; 88 Suppl 1():S30-9. PubMed ID: 21109066
    [Abstract] [Full Text] [Related]

  • 5. Preclinical evaluation of anti-HIV microbicide products: New models and biomarkers.
    Doncel GF, Clark MR.
    Antiviral Res; 2010 Dec; 88 Suppl 1():S10-8. PubMed ID: 21109063
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide.
    Woolfson AD, Malcolm RK, Morrow RJ, Toner CF, McCullagh SD.
    Int J Pharm; 2006 Nov 15; 325(1-2):82-9. PubMed ID: 16884869
    [Abstract] [Full Text] [Related]

  • 8. Mucoadhesive nanosystems for vaginal microbicide development: friend or foe?
    das Neves J, Amiji M, Sarmento B.
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2011 Nov 15; 3(4):389-99. PubMed ID: 21506290
    [Abstract] [Full Text] [Related]

  • 9. Microbicides: putting women in control.
    Forbes A.
    WORLD; 1998 Sep 15; (89):4-5. PubMed ID: 11365770
    [Abstract] [Full Text] [Related]

  • 10. Clinical evaluation of microbicide formulations.
    Morrow KM, Hendrix C.
    Antiviral Res; 2010 Dec 15; 88 Suppl 1(Suppl 1):S40-6. PubMed ID: 21109067
    [Abstract] [Full Text] [Related]

  • 11. Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection.
    Ham AS, Ugaonkar SR, Shi L, Buckheit KW, Lakougna H, Nagaraja U, Gwozdz G, Goldman L, Kiser PF, Buckheit RW.
    J Pharm Sci; 2012 Apr 15; 101(4):1423-35. PubMed ID: 22227864
    [Abstract] [Full Text] [Related]

  • 12. The future of HIV prevention: prospects for an effective anti-HIV microbicide.
    Nuttall J, Romano J, Douville K, Galbreath C, Nel A, Heyward W, Mitchnick M, Walker S, Rosenberg Z.
    Infect Dis Clin North Am; 2007 Mar 15; 21(1):219-39, x. PubMed ID: 17502237
    [Abstract] [Full Text] [Related]

  • 13. Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies?
    Martinez J, Coplan P, Wainberg MA.
    Antiviral Res; 2006 Sep 15; 71(2-3):343-50. PubMed ID: 16787667
    [Abstract] [Full Text] [Related]

  • 14. In vitro profiling of the vaginal permeation potential of anti-HIV microbicides and the influence of formulation excipients.
    Grammen C, Augustijns P, Brouwers J.
    Antiviral Res; 2012 Nov 15; 96(2):226-33. PubMed ID: 23000496
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission.
    Friend DR.
    Expert Opin Drug Deliv; 2012 Apr 15; 9(4):417-27. PubMed ID: 22385316
    [Abstract] [Full Text] [Related]

  • 18. Recommendations for the development of vaginal microbicides. International Working Group on Vaginal Microbicides.
    AIDS; 1996 Jul 15; 10(8):1-6. PubMed ID: 8828760
    [Abstract] [Full Text] [Related]

  • 19. Heterosexual anal intercourse has the potential to cause a significant loss of power in vaginal microbicide effectiveness studies.
    McGowan I, Taylor DJ.
    Sex Transm Dis; 2010 Jun 15; 37(6):361-4. PubMed ID: 20514687
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.